Great Hill Capital LLC Takes $8.27 Million Position in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Great Hill Capital LLC picked up 723,285 shares of DENTSPLY SIRONA (NASDAQ:XRAY) in Q4, a new position worth about $8.27 million that represents roughly 0.36% ownership and is the firm's 14th-largest holding.
• Company directors James D. Forbes and Gregory T. Lucier bought 5,000 and 15,000 shares respectively in March at about $12.45–$12.48 per share, and insiders acquired 70,000 shares (~$956k) in the last quarter, indicating insider buying activity.
• Analyst sentiment is mixed with an average rating of Hold and a consensus target of $14.08 (3 Buys, 9 Holds, 3 Sells); XRAY trades near $12.05 with a $2.41B market cap and the company set FY2026 guidance of 1.40–1.50 EPS versus analyst forecasts around 1.84 EPS.

Great Hill Capital LLC acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 723,285 shares of the medical instruments supplier's stock, valued at approximately $8,267,000. DENTSPLY SIRONA accounts for about 0.8% of Great Hill Capital LLC's holdings, making the stock its 14th largest holding. Great Hill Capital LLC owned 0.36% of DENTSPLY SIRONA at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the 1st quarter worth $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,122 shares during the last quarter. Huntington National Bank increased its stake in shares of DENTSPLY SIRONA by 292.9% in the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier's stock worth $35,000 after purchasing an additional 2,077 shares during the period. True Wealth Design LLC lifted its position in shares of DENTSPLY SIRONA by 49.7% during the 3rd quarter. True Wealth Design LLC now owns 3,557 shares of the medical instruments supplier's stock worth $45,000 after purchasing an additional 1,181 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of DENTSPLY SIRONA by 119.1% during the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier's stock worth $43,000 after purchasing an additional 2,051 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director James D. Forbes purchased 5,000 shares of the stock in a transaction on Monday, March 9th. The shares were purchased at an average price of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director directly owned 10,000 shares of the company's stock, valued at $124,800. This represents a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gregory T. Lucier acquired 15,000 shares of the company's stock in a transaction dated Monday, March 9th. The stock was acquired at an average price of $12.45 per share, with a total value of $186,750.00. Following the purchase, the director owned 65,000 shares in the company, valued at approximately $809,250. This represents a 30.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 70,000 shares of company stock worth $956,437 in the last quarter. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Barrington Research raised their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an "outperform" rating in a report on Monday, March 2nd. Citigroup began coverage on DENTSPLY SIRONA in a research report on Wednesday. They issued a "sell" rating and a $10.00 price objective for the company. Bank of America upgraded shares of DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Zacks Research raised shares of DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a research report on Monday, March 2nd. Finally, UBS Group cut their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $14.08.

DENTSPLY SIRONA Trading Down 1.4%

DENTSPLY SIRONA stock opened at $12.05 on Thursday. The business has a 50 day moving average price of $12.38 and a two-hundred day moving average price of $12.07. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA Inc. has a 12 month low of $9.85 and a 12 month high of $17.18. The stock has a market cap of $2.41 billion, a price-to-earnings ratio of -4.02, a price-to-earnings-growth ratio of 1.44 and a beta of 0.99.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.01). The firm had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.26 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.